- Details
- In this educational initiative, focusing on the knowledge of PSMA PET imaging and PSMA theranostics, Drs Ken Herrmann and Johannes Czernin discuss a case of a 61 year old patient diagnosed with prostate cancer in 2010. An initial TNM classification was cT2, cN1, M1c and lymphadenectomy and prostatectomy were performed. The patient resurfaced to the urologist in February 2019 when there was a PSA i...
|
- Details
- In this educational initiative, focusing on the knowledge of PSMA PET imaging and PSMA theranostics, Drs Jeremie Calais, Michael Morris, and Alberto Briganti discuss a biochemical recurrence patient case and the impact PSMA PET can have on radiation therapy planning or treatment. In this surgical case a 60-year-old gentleman who had radical prostatectomy in 2016 was pT2c node-negative, margin nega...
|
- Details
- In this educational initiative, focusing on the knowledge of PSMA PET imaging and PSMA theranostics, Drs Jeremie Calais, Michael Morris, and Alberto Briganti gather for a PSMA PET Academy discussion on biochemical recurrence cases and the impact of what PSMA PET can have on radiation therapy planning or treatment management. In this case, a patient had surgery in 2007 for pT3bN0M0 margin-negative...
|
- Details
- In this educational initiative, focusing on the knowledge of PSMA PET imaging and PSMA theranostics, Drs Oliver Sartor and Bernd Krause discuss PSMA-PET/CT before and after PSMA radioligand therapy with mismatch example for liver metastases. Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies: Prof. Dr. med. Bernd J. Krause, Nuclear Medicine Physic...
|
- Details
- In this educational initiative, focusing on the knowledge of PSMA PET imaging and PSMA theranostics, Drs Stefano Fanti, Christopher Sweeney, and Neal Shore discuss a controversial topic on what to do when you have bone findings at PSMA PET with no CT counterpart. Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies: Stefano Fanti, MD, Professor, Dep...
|
- Details
- In this educational initiative, focusing on the knowledge of PSMA PET imaging and PSMA theranostics, Drs Thomas Hope, Nicola Fossati, Robert Reiter, and Bertrand Tombal discuss a series of five cases focusing on how PSMA-PET impacts the management of prostate cancer patients. Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies: Thomas Hope, MD, Ass...
|
- Details
- In this educational initiative, focusing on the knowledge of PSMA PET imaging and PSMA theranostics, Andrea Farolfi presents the clinician's view on reading and reporting a PSMA PET scan. He highlights the PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE) as well as PSMA PET progression criteria (PPP) to define prostate cancer progression by PSMA PET and what is important in a PS...
|
- Details
- In this educational initiative, focusing on the knowledge of PSMA PET and PSMA theranostics, Jeremie Calais presents on understanding the physiological PSMA biodistribution and the pathological uptake of the use of PSMA for prostate cancer. Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies: Jeremie Calais, MD, MSc, Director, Clinical Research Pro...
|
- Details
- In this educational initiative, focusing on the knowledge of PSMA PET and PSMA theranostics, Drs Matthias Eiber and Thomas Langbein jointly prepared and Dr Eiber presents on the Dark Side of PSMA: Pitfalls, Limits, and ADT for prostate cancer. Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies: Matthias Eiber, MD, PhD, Department of Nuclear Medici...
|
- Details
- In this educational initiative, focusing on the knowledge of PSMA PET and PSMA treatment, Oliver Sartor presents PSMA PET in the metastatic castration-resistant prostate cancer setting with the goal of treatment and an outlook on PSMA therapy. He focuses on this in the context of The VISION Trial: Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. Independent Medical Educat...
|
